Novo Nordisk just suffered its worst single-day drop in history—falling 25%—after slashing its 2025 sales and profit forecast tied to its flagship weight-loss drug Wegovy. The pharmaceutical giant is facing serious headwinds, including over 1 million U.S. patients using cheaper, compounded versions of semaglutide. Novo has filed lawsuits against telehealth companies like Hims & Hers, but the damage may already be done. With shares down 65% from their 2023 peak, analysts now question whether the weight-loss drug trade is topping out. Watch this breakdown to understand what’s really happening—and what it could mean for the future of obesity drugs, investors, and the healthcare industry. 🌐 Want more market-moving insights? Dive deeper at benzinga.com — your one-stop destination for the latest financial news, data, and expert analysis to stay ahead of the markets. 📲 Let’s stay connected! Follow us for real-time updates, market tips, and exclusive content: 🔹 Instagram: www...